Literature DB >> 6628932

Adult cystic fibrosis: postprandial response of gut regulatory peptides.

J M Allen, A R Penketh, T E Adrian, Y C Lee, D L Sarson, M E Hodson, J C Batten, S R Bloom.   

Abstract

Responses of 11 gastrointestinal regulatory peptides to a standard test meal were assessed in 10 adult patients with cystic fibrosis. The basal plasma neurotensin was significantly elevated in patients with cystic fibrosis, being 31.5 +/- 6.1 pmol/L compared with a control value of 10.3 +/- 1.5 pmol/L (p less than 0.005). Plasma neurotensin remained elevated throughout the test period. Basal plasma enteroglucagon was similarly elevated, the patients with fibrocystic disease having levels of 51.3 +/- 4.6 pmol/L compared to controls with levels of 33.2 +/- 6.7 pmol/L (p less than 0.02). There was, however, no significant difference in postprandial levels of plasma enteroglucagon. Postprandial motilin was significantly elevated in the patients with cystic fibrosis; this elevation is in contrast with previous findings in children. Release of gastric inhibitory polypeptide was impaired, while release of cholecystokinin showed no significant difference in control values, although there was a tendency for delay. There was no significant postprandial rise of pancreatic polypeptide in the patients, whose levels were grossly lower than controls. Insulin showed a delayed response. No significant differences were observed between patients and controls in levels of gastrin, pancreatic glucagon, somatostatin, or vasoactive intestinal peptide. The elevation of plasma neurotensin and enteroglucagon in the basal state may reflect an adaptive response and may be part of the improved digestive function in adults compared with children with fibrocystic disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628932

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

Review 1.  Rationale of modern dietary recommendations in cystic fibrosis.

Authors:  J M Littlewood; A MacDonald
Journal:  J R Soc Med       Date:  1987       Impact factor: 5.344

Review 2.  Perspectives of CCK antagonists in pancreatic research and clinical use. Part I.

Authors:  L C Rovati
Journal:  Int J Pancreatol       Date:  1991-04

Review 3.  Gastrointestinal tract and nutrition in cystic fibrosis: pathophysiology.

Authors:  J A Dodge
Journal:  J R Soc Med       Date:  1986       Impact factor: 5.344

Review 4.  Cystic fibrosis--a gastroenterological cornucopia.

Authors:  P L Zentler-Munro
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

5.  Plasma CCK levels in patients with pancreatic insufficiency.

Authors:  T Bozkurt; G Adler; I Koop; H Koop; W Türmer; R Arnold
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

Review 6.  Survival in a bad neighborhood: pancreatic islets in cystic fibrosis.

Authors:  Andrew W Norris; Katie Larson Ode; Lina Merjaneh; Srinath Sanda; Yaling Yi; Xingshen Sun; John F Engelhardt; Rebecca L Hull
Journal:  J Endocrinol       Date:  2019-02-01       Impact factor: 4.286

7.  Gut hormones and gastrointestinal motility in children with cystic fibrosis.

Authors:  M S Murphy; A L Brunetto; A D Pearson; M A Ghatei; R Nelson; E J Eastham; S R Bloom; A A Green
Journal:  Dig Dis Sci       Date:  1992-02       Impact factor: 3.199

8.  Cystic fibrosis associated islet changes may provide a basis for diabetes. An immunocytochemical and morphometrical study.

Authors:  M Löhr; P Goertchen; H Nizze; N S Gould; V E Gould; M Oberholzer; P U Heitz; G Klöppel
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

9.  Cystic fibrosis in adolescents and adults.

Authors:  A R Penketh; A Wise; M B Mearns; M E Hodson; J C Batten
Journal:  Thorax       Date:  1987-07       Impact factor: 9.139

10.  Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas.

Authors:  H G Heijerman; C B Lamers; W Bakker; J H Dijkman
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.